Bayer and Aignostics to collaborate on next generation precision oncology
- Details
- Category: Bayer

AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
- Details
- Category: AstraZeneca

The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism.
European Commission approves Pfizer's PREVENAR 20® to help protect infants and children against pneumococcal disease
- Details
- Category: Pfizer

Novartis presents new data on safety and efficacy of Zolgensma
- Details
- Category: Novartis

Pfizer announces positive top-line data for full season two efficacy of ABRYSVO® for RSV in older adults
- Details
- Category: Pfizer

Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
- Details
- Category: Bayer

European Commission approves Pfizer's VELSIPITY® for patients with moderately to severely Active ulcerative colitis
- Details
- Category: Pfizer

More Pharma News ...
- Acquisition of Icosavax completed
- First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
- Vividion Therapeutics starts Phase I clinical trial in advanced solid and hematologic tumors with oral STAT3 inhibitor
- The American Cancer Society and Pfizer announce a $15 million, three-year initiative to bridge the gap in cancer care disparities
- Bayer aims to sustainably improve performance with new organization
- Pfizer recommends shareholders reject the below-market mini-tender offer by TRC Capital Investment Corporation
- European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types